Oh... So that's why I'm having a second dose of Evushield tomorrow. They increased the initial dose a week after my treatment. I didn't recall being told it was a two dose treatment initially. From Seattle Cancer Care Alliance: Evusheld While vaccines play a critical role in keeping you safe, we recognize that some of you may not have a strong response to COVID-19 vaccination. If you meet the eligibility requirements listed below and supply is available, you may be able to receive Evusheld (tixagevimab and cilgavimab), a medication used to prevent COVID-19 infection before you are exposed to the virus. Evusheld is not used to treat COVID-19 infection or for people with known exposure to COVID-19. Evusheld is not a replacement for COVID-19 vaccination. If you can safely get the COVID-19 vaccine and have not already, we encourage you to do so. If you are not sure if the vaccine is safe for you, please ask your care team. Who is eligible for Evusheld? Currently, there is a limited supply of Evusheld available. We are prioritizing our most immunocompromised patients based on National Institutes of Health guidelines, which include: Active pre-transplant/HCT within one year, those with chronic GVHD or who are taking immunosuppressive medications for another indication. CAR T cell recipients Hematologic malignancy patients on active therapy Patients who are within 1 year of receiving B-cell depleting therapies Patients receiving Bruton tyrosine kinase inhibitors Patients with severe combined immunodeficiencies Lung transplant recipients Patients who are within 1 year of receiving a solid-organ transplant (other than lung transplant) Solid-organ transplant recipients with recent treatment for acute rejection with T or B cell depleting agents Patients with untreated HIV who have a CD4 T lymphocyte cell count <50 cells/mm³ If you are eligible to receive Evusheld, your care team will discuss this with you at an upcoming appointment. If, after your conversation with your care team, you decide you want to take Evusheld, you’ll be added to a waitlist and contacted when it is your turn. We will re-evaluate eligibility criteria as supply allows and will keep you updated when more patients become eligible for this treatment. Recent changes to Evusheld dose On February 24, the U.S. Food and Drug Administration (FDA) revised the emergency use authorization (EUA) for Evusheld to increase the initial dose. The dose was revised based on information that shows a higher dose of Evusheld may be more likely to prevent infection by the COVID-19 Omicron subvariants. If you already received an initial dose of Evusheld: Your care team will contact you in the coming weeks, if they have not already done so, to schedule a second dose. If you decline a second dose when it’s offered to you and later change your mind, you may contact your care team at any time and tell them you would like to be scheduled.
